HCN3 and triple-negative breast carcinoma: Given the therapeutic potential of HCN3 inhibits the treatment of triple-negative breast cancer and sleep disorders, the structure of HCN3 insights reveal critical interactions in a key state of the channel, which will allow medicinal chemists and computational biologists to design new potent and subtype-specific inhibitors.